https://www.selleckchem.com/pr....oducts/FK-506-(Tacro
Targeting the Wnt signaling pathway via modulating CAF may be a potential therapeutic approach.Background Osimertinib efficacy in pre-treated patients with epidermal growth factor receptor (EGFR) T790M-mutated non-small cell lung cancer (NSCLC) has been demonstrated in clinical trials, but real-world data, particularly regarding resistance profile, remains limited. This study aims to analyze the resistance mechanisms acquired after treatment with Osimertinib. Methods Clinical outcomes and molecular results from re-biopsies a
Like
Comment
Share
